GlassScriptPhysician profile
Joel M Adams
NPI 1548614118
$3,727.34
in general payments reported to CMS, 2019-2025
24 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 94% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.40 · 2023: $762 · 2024: $1,503 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,620 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,619.95 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,514.91 | 2022-2025 | Rinvoq, Skyrizi, Vraylar |
| Amgen INC. | $438.57 | 2023-2025 | Enbrel, Evenity, Tavneos |
| Janssen Biotech, INC. | $332.53 | 2024-2025 | Tremfya |
| Glaxosmithkline, LLC. | $281.74 | 2023-2025 | Benlysta |
| Genzyme Corporation | $242.18 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $208.29 | 2023-2025 | |
| Sobi, INC | $126.78 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.93 | 2023-2024 | Cyltezo, Tradjenta, Jardiance |
| Scilex Pharmaceuticals INC. | $68.32 | 2024 | |
| Dexcom, INC. | $64.55 | 2023 | Dexcom G6 Transmitter |
| Ucb, INC. | $47.38 | 2024-2025 | Bimzelx, Cimzia |
| Tonix Medicines, INC. | $36.76 | 2025 | Tonmya |
| Astrazeneca Pharmaceuticals LP | $31.55 | 2023-2024 | Breztri |
| E.R. Squibb & Sons, L.L.C. | $30.10 | 2024-2025 | Orencia |
| Axsome Therapeutics, INC. | $29.65 | 2023 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $26.57 | 2024 | |
| Invivyd INC | $23.10 | 2025 | Pemgarda |
| Biocon Biologics INC | $21.28 | 2024 | Hulio |
| Sumitomo Pharma America, INC. | $20.14 | 2023 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $19.39 | 2023 | Rexulti |
| Lilly USA, LLC | $18.33 | 2023 | Trulicity, Mounjaro |
| Idorsia Pharmaceuticals US INC | $16.99 | 2022 | |
| Pfizer INC. | $14.77 | 2023 | |
| Novo Nordisk INC | $14.53 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.